Ibrutinib, a BTK inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity in allergic cancer patients receiving drug

被引：1

作者：

Regan, Jennifer A. ^{[1
]}

Petrich, Adam M. ^{[2
,3
]}

Dispenza, Melanie C. ^{[1
]}

Ma, Shuo ^{[2
]}

Gordon, Leo I. ^{[2
]}

Bochner, Bruce S. ^{[1
]}

机构：

[1] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA

[3] AbbVie Inc, Chicago, IL USA

来源：

关键词：

D O I：

10.1016/j.jaci.2016.12.748

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

729

引用

页码：AB232 / AB232

页数：1